Therapies for mobility disability in persons with multiple sclerosis

References

• National Multiple Sclerosis Society. Multiple Sclerosis Information Sourcebook. New York, NY: Information Resource Center and Library of the National Multiple Sclerosis Society; 2005.
   Google Scholar
• Hemmer B, Nessler S, Zhou D, et al. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol. 2006;2(4):201–211.
   PubMedGoogle Scholar
• Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001;14(3):271–278.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269.
   PubMed Web of Science ®Google Scholar
• Benedict RH, Holtzer R, Motl RW, et al. Upper and lower extremity motor function and cognitive impairment in multiple sclerosis. J Int Neuropsychol Soc. 2011;17(4):643–653.
   PubMed Web of Science ®Google Scholar
• Hobart J, Riazi A, Lamping D, et al. Measuring the impact of MS on walking ability the 12-item MS Walking Scale (MSWS-12). Neurology. 2003;60(1):31–36.
   PubMed Web of Science ®Google Scholar
• Hobart J, Lamping D, Fitzpatrick R, et al. The multiple sclerosis impact scale (MSIS-29) a new patient-based outcome measure. Brain. 2001;124(5):962–973.
   PubMedGoogle Scholar
• Swingler R, Compston D. The morbidity of multiple sclerosis. Qjm-Int J Med. 1992;83(1):325–337.
   PubMedGoogle Scholar
• Van Asch P. Impact of mobility impairment in multiple sclerosis 2–patients’ perspectives. Eur Neurol Rev. 2011;6(2):115–120.
   Google Scholar
• Heesen C, Böhm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler. 2008;14(7):988–991.
   PubMedGoogle Scholar
• LaRocca NG. Impact of walking impairment in multiple sclerosis. Patient. 2011;4(3):189–201.
   PubMedGoogle Scholar
• Iezzoni L. When walking fails: mobility problems of adults with chronic conditions. Vol. 8, Univ of California Press; 2003.
   Google Scholar
• Wingerchuk DM, Carter JL, editors. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo clinic proceedings. Elsevier; 2014.
   Google Scholar
• Cross A, Naismith R. Established and novel disease‐modifying treatments in multiple sclerosis. J Intern Med. 2014;275(4):350–363.
   PubMed Web of Science ®Google Scholar
• Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investig Med 2017. jim-2016-000339.
   PubMedGoogle Scholar
• Hemmett L, Holmes J, Barnes M, et al. What drives quality of life in multiple sclerosis? Qjm-Int J Med. 2004;97(10):671–676.
   PubMed Web of Science ®Google Scholar
• Chan A, Heck C. Mobility in multiple sclerosis: more than just a physical problem. Int J MS Care. 2000;2(1):51–61.
   Google Scholar
• Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17:S146–S153.
   PubMedGoogle Scholar
• Feinstein A, Freeman J, Lo AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14(2):194–207.
   PubMed Web of Science ®Google Scholar
• Newsome SD, Aliotta PJ, Bainbridge J, et al. A framework of care in multiple sclerosis, part 2: symptomatic care and beyond. Int J MS Care. 2017;19(1):42–56.
   PubMedGoogle Scholar
• Mehr SR, Zimmerman MP. Reviewing the unmet needs of patients with multiple sclerosis. Am Health Drug Benefits. 2015;8(8):426.
   PubMed Web of Science ®Google Scholar
• Blight AR, Henney HR, Cohen R. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis. ANN NY Acad Sci. 2014;1329(1):33–44.
   PubMedGoogle Scholar
• Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732–738.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Schapiro RT, et al. A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. Int J MS Care. 2014;16(3):153–160.
   PubMedGoogle Scholar
• Goodman A, Brown T, Cohen J, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71(15):1134–1141.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494–502.
   PubMed Web of Science ®Google Scholar
• Behm K, Morgan P. The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review. Disabil Rehabil. 2017;1–12.
   Google Scholar
• Goldman MD, Motl RW, Scagnelli J, et al. Clinically meaningful performance benchmarks in MS timed 25-foot walk and the real world. Neurology. 2013;81(21):1856–1863.
   PubMed Web of Science ®Google Scholar
• Yapundich R, Applebee A, Bethoux F, et al. Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis: a randomized controlled trial. Int J MS Care. 2015;17(3):138–145.
   PubMedGoogle Scholar
• Learmonth YC, Dlugonski DD, Pilutti LA, et al. The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis. Mult Scler. 2013;19(13):1784–1791.
   PubMed Web of Science ®Google Scholar
• Zörner B, Filli L, Reuter K, et al. Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern. Mult Scler. 2016;22(11):1463–1475.
   PubMed Web of Science ®Google Scholar
• Plummer P. Critical appraisal of evidence for improving gait speed in people with multiple sclerosis: dalfampridine versus gait training. Int J MS Care. 2016;18(3):105–115.
   PubMedGoogle Scholar
• Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin. 2011;27(7):1415–1423.
   PubMed Web of Science ®Google Scholar
• Jensen HB, Ravnborg M, Dalgas U, et al. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014;7(2):97–113.
   PubMed Web of Science ®Google Scholar
• Zeller D, Classen J. Plasticity of the motor system in multiple sclerosis. Neuroscience. 2014;283:222–230.
   PubMed Web of Science ®Google Scholar
• Brambilla L, Sebastiano DR, Aquino D, et al. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness. J Neurol Sci. 2016;368:402–407.
   PubMed Web of Science ®Google Scholar
• Dalgas U, Stenager E. Progressive resistance therapy is not the best way to rehabilitate deficits due to multiple sclerosis: no. Mult Scler. 2014;20(2):141–142.
   PubMed Web of Science ®Google Scholar
• Motl RW, Mowry EM, Ehde DM, et al. Wellness and multiple sclerosis: the National MS society establishes a wellness research working group and research priorities. Mult Scler. 2017.
   Web of Science ®Google Scholar
• Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 2005;4(10):643–652.
   PubMed Web of Science ®Google Scholar
• Snook EM, Motl RW. Effect of exercise training on walking mobility in multiple sclerosis: a meta-analysis. Neurorehabil Neural Repair. 2009;23(2):108–116.
   PubMed Web of Science ®Google Scholar
• Motl RW. Ambulation and multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(2):325–336.
   PubMed Web of Science ®Google Scholar
• Motl RW, Pilutti LA. The benefits of exercise training in multiple sclerosis. Nat Rev Neurosci. 2012;8(9):487–497.
   Google Scholar
• Motl RW. Physical activity and irreversible disability in multiple sclerosis. Exerc Sport Sci Rev. 2010;38(4):186–191.
   PubMed Web of Science ®Google Scholar
• Sandroff BM, Klaren RE, Motl RW. Relationships among physical inactivity, deconditioning, and walking impairment in persons with multiple sclerosis. J Neurol Phys Ther. 2015;39(2):103–110.
   PubMed Web of Science ®Google Scholar
• Bouchard CE, Shephard RJ, Stephens TE, editors. Physical activity, fitness, and health: international proceedings and consensus statement. International Consensus Symposium on Physical Activity, Fitness, and Health, 2nd, May, 1992, 1994 Toronto, ON, Canada: Human Kinetics Publishers.
   Google Scholar
• Pilutti LA, Platta ME, Motl RW, et al. The safety of exercise training in multiple sclerosis: a systematic review. J Neurol Sci. 2014;343(1):3–7.
   PubMed Web of Science ®Google Scholar
• Latimer-Cheung AE, Pilutti LA, Hicks AL, et al. Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development. Arch Phys Med Rehabil. 2013;94(9):1800–1828. e3.
   PubMed Web of Science ®Google Scholar
• Pearson M, Dieberg G, Smart N. Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil. 2015;96(7):1339–1348. e7.
   PubMed Web of Science ®Google Scholar
• Edwards T, Pilutti LA. The effect of exercise training in adults with multiple sclerosis with severe mobility disability: a systematic review and future research directions. Mult Scler Relat Disord. 2017;16:31-39.
   Web of Science ®Google Scholar
• Cakit BD, Nacir B, Genç H, et al. Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Rehabil. 2010;89(6):446–457.
   PubMed Web of Science ®Google Scholar
• Sandroff BM, Bollaert RE, Pilutti LA, et al. Multimodal exercise training in multiple sclerosis: A randomized controlled trial in persons with substantial mobility disability. Contem Clin Trials. 2017;61:39–47.
   PubMed Web of Science ®Google Scholar
• Sandroff BM, Sosnoff JJ, Motl RW. Physical fitness, walking performance, and gait in multiple sclerosis. J Neurol Sci. 2013;328(1):70–76.
   PubMed Web of Science ®Google Scholar
• Motl RW, Goldman MD, Benedict RH. Walking impairment in patients with multiple sclerosis: exercise training as a treatment option. Neuropsychiatr Dis Treat. 2010;6:767.
   PubMed Web of Science ®Google Scholar
• Briken S, Gold S, Patra S, et al. Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial. Mult Scler. 2014;20(3):382–390.
   PubMed Web of Science ®Google Scholar
• Kjølhede T, Vissing K, de Place L, et al. Neuromuscular adaptations to long-term progressive resistance training translates to improved functional capacity for people with multiple sclerosis and is maintained at follow-up. Mult Scler. 2015;21(5):599–611.
   PubMed Web of Science ®Google Scholar
• Motl RW, Pilutti LA, Hubbard EA, et al. Cardiorespiratory fitness and its association with thalamic, hippocampal, and basal ganglia volumes in multiple sclerosis. Neuroimage Clin. 2015;7:661–666.
   PubMed Web of Science ®Google Scholar
• Motl RW, Hubbard EA, Sreekumar N, et al. Pallidal and caudate volumes correlate with walking function in multiple sclerosis. J Neurol Sci. 2015;354(1):33–36.
   PubMed Web of Science ®Google Scholar
• Klaren RE, Hubbard EA, Motl RW, et al. Objectively measured physical activity is associated with brain volumetric measurements in multiple sclerosis. Behav Neurol. 2015;2015.
   PubMedGoogle Scholar
• Fritz NE, Keller J, Calabresi PA, et al. Quantitative measures of walking and strength provide insight into brain corticospinal tract pathology in multiple sclerosis. NeuroImage Clin. 2017;14:490–498.
   PubMed Web of Science ®Google Scholar
• Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108(7):3017–3022.
   PubMed Web of Science ®Google Scholar
• Rossi S, Furlan R, De Chiara V, et al. Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiol Dis. 2009;36(1):51–59.
   PubMed Web of Science ®Google Scholar
• Wiles C, Newcombe R, Fuller K, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70(2):174–179.
   PubMed Web of Science ®Google Scholar
• Hogan N, Coote S. Therapeutic interventions in the treatment of people with multiple sclerosis with mobility problems: a literature review. Phys Ther Rev. 2009;14(3):160–168.
   Google Scholar
• Paltamaa J, Sjögren T, Peurala SH, et al. Effects of physiotherapy interventions on balance in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. J Rehabil Med Suppl. 2012;44(10):811–823.
   PubMed Web of Science ®Google Scholar
• Learmonth YC, Ensari I, Motl RW. Physiotherapy and walking outcomes in adults with multiple sclerosis: systematic review and meta-analysis. Phys Ther Rev. 2016;21(36):160–172.
   Google Scholar
• Gunn H, Markevics S, Haas B, et al. Systematic review: the effectiveness of interventions to reduce falls and improve balance in adults with multiple sclerosis. Arch Phys Med Rehabil. 2015;96(10):1897–1912.
   Web of Science ®Google Scholar
• Sosnoff JJ, Sung J. Reducing falls and improving mobility in multiple sclerosis. Expert Rev Neurother. 2015;15(6):655–666.
   PubMed Web of Science ®Google Scholar
• Morgen K, Kadom N, Sawaki L, et al. Training-dependent plasticity in patients with multiple sclerosis. Brain. 2004;127(11):2506–2517.
   PubMedGoogle Scholar
• Iyigun G, Yildirim SA, Snowdon N. Is physiotherapy effective in improving balance and gait in patients with multiple sclerosis?: a systematic review. J Med Sci. 2010;30(2):482–493.
   Google Scholar
• Lord S, Wade D, Halligan P. A comparison of two physiotherapy treatment approaches to improve walking in multiple sclerosis: a pilot randomized controlled study. Clin Rehabil. 1998;12(6):477–486.
   PubMed Web of Science ®Google Scholar
• Givon U, Zeilig G, Achiron A. Gait analysis in multiple sclerosis: characterization of temporal–spatial parameters using GAITRite functional ambulation system. Gait Posture. 2009;29(1):138–142.
   PubMed Web of Science ®Google Scholar
• Pilutti LA, Paulseth JE, Dove C, et al. Exercise training in progressive multiple sclerosis: a comparison of recumbent stepping and body weight–supported treadmill training. Int J MS Care. 2016;18(5):221–229.
   PubMedGoogle Scholar
• Xie X, Sun H, Zeng Q, et al. Do patients with multiple sclerosis derive more benefit from robot-assisted gait training compared with conventional walking therapy on motor function? A meta-analysis. Front Neurol. 2017;8:260.
   PubMed Web of Science ®Google Scholar
• Lo AC, Triche EW. Improving gait in multiple sclerosis using robot-assisted, body weight supported treadmill training. Neurorehabil Neural Repair. 2008;22(6):661–671.
   PubMed Web of Science ®Google Scholar
• Beer S, Aschbacher B, Manoglou D, et al. Robot-assisted gait training in multiple sclerosis: a pilot randomized trial. Mult Scler. 2008;14(2):231–236.
   PubMedGoogle Scholar
• Schwartz I, Sajin A, Moreh E, et al. Robot-assisted gait training in multiple sclerosis patients: a randomized trial. Mult Scler. 2012;18(6):881–890.
   PubMed Web of Science ®Google Scholar
• Baert I, Freeman J, Smedal T, et al. Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European multicenter study. Neurorehabil Neural Repair. 2014;28(7):621–631.
   PubMed Web of Science ®Google Scholar
• Pompa A, Morone G, Iosa M, et al. Does robot-assisted gait training improve ambulation in highly disabled multiple sclerosis people? A pilot randomized control trial. Mult Scler. 2017;23(5):696–703.
   PubMed Web of Science ®Google Scholar
• Gandolfi M, Geroin C, Picelli A, et al. Robot-assisted vs. sensory integration training in treating gait and balance dysfunctions in patients with multiple sclerosis: a randomized controlled trial. Front Hum Neurosci. 2014;8:318.
   PubMed Web of Science ®Google Scholar
• Plummer P, Williams AA, Bohling CJ, et al. Combining dalfampridine with physical therapy may improve treatment effects in dalfampridine non-responders with multiple sclerosis: a case study. Arch Phys Med Rehabil. 2016;97(10):e62.
   Google Scholar
• Stough DK, Harrison-Cudnik M, Mays J, et al. Combining physical therapy with dalfampridine in patients with multiple sclerosis. Annual Meeting of the Consortium of Multiple Sclerosis Centers; Orlando, FL: Int J MS Care; 2013.
   Google Scholar
• Holtzer R, Mahoney JR, Izzetoglu M, et al. fNIRS study of walking and walking while talking in young and old individuals. J Gerontol A Biol Sci Med Sci. 2011;66(8):879–887.
   PubMed Web of Science ®Google Scholar
• Fritz NE, Cheek FM, Nichols-Larsen DS. Motor-cognitive dual-task training in neurologic disorders: a systematic review. J Neurol Phys Ther. 2015;39(3):142.
   PubMed Web of Science ®Google Scholar
• Motl RW, Sandroff BM, DeLuca J. Exercise training and cognitive rehabilitation: a symbiotic approach for rehabilitating walking and cognitive functions in multiple sclerosis? Neurorehabil Neural Repair. 2016;30(6):499–511.
   PubMed Web of Science ®Google Scholar
• Law LL, Barnett F, Yau MK, et al. Effects of combined cognitive and exercise interventions on cognition in older adults with and without cognitive impairment: a systematic review. Ageing Res Rev. 2014;15:61–75.
   PubMed Web of Science ®Google Scholar
• Hamilton F, Rochester L, Paul L, et al. Walking and talking: and investigation of cognitive-motor dual tasking in multiple sclerosis. Mult Scler. 2009;15(10):1215–1227.
   PubMed Web of Science ®Google Scholar
• Leone C, Patti F, Feys P. Measuring the cost of cognitive-motor dual tasking during walking in multiple sclerosis. Mult Scler. 2015;21(2):123–131.
   PubMed Web of Science ®Google Scholar
• Sosnoff JJ, Socie MJ, Sandroff BM, et al. Mobility and cognitive correlates of dual task cost of walking in persons with multiple sclerosis. Disabil Rehabil. 2014;36(3):205–209.
   PubMed Web of Science ®Google Scholar
• Sosnoff JJ, Wajda DA, Sandroff BM, et al. Dual task training in persons with multiple sclerosis: a feasability randomized controlled trial. Clin Rehabil. 2017;31(10):1322–1331.
   PubMed Web of Science ®Google Scholar
• Ahtiainen JP, Walker S, Peltonen H, et al. Heterogeneity in resistance training-induced muscle strength and mass responses in men and women of different ages. Age. 2016;38(1):10.
   PubMedGoogle Scholar
• Mäurer M, Schuh K, Seibert S, et al. A randomized study to evaluate the effect of exercise on fatigue in people with relapsing–remitting multiple sclerosis treated with fingolimod. Mult Scler J Exp Transl Clin. 2018;4(1). 2055217318756688.
   PubMedGoogle Scholar
• Motl RW, Learmonth YC, Pilutti LA, et al. Top 10 research questions related to physical activity and multiple sclerosis. Res Q Exerc Sport. 2015;86(2):117–129.
   PubMed Web of Science ®Google Scholar